Here’s what you should know:
1. Dr. Alistar has been at the forefront of CPI-613 research. She conducted early stage clinical trials of the treatment and will serve as co-principal investigator on a phase-III combination therapy study of CPI-613 and modified Folfirinox.
2. In addition to this upcoming study, Dr. Alistar led four other clinical trials for CPI-613, as well as several for oncology drugs.
3. She said, “Pancreatic cancer has a very low survival rate. This is due in part to the fact that it is often discovered in a late stage. Early detection can make a difference.”
More articles on gastroenterology:
Tufts Medical Center, Texas Gastroenterology Institute & more: 6 GI practices in the news
FDA approves Synergy Pharmaceuticals’ Trulance for adults with IBS-C — 3 insights
AGA launches patient app aimed at IBD monitoring, education — 3 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
